Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of May 2021. The report details the completion of an Exchange Offer to replace eligible employee stock options with new options featuring modified terms.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures for the reporting period. The document focuses exclusively on the mechanics of the option exchange.
- Options Exchanged: 2,805,281 American Depositary Shares (ADSs) underlying eligible options were cancelled.
- New Options Granted: 2,805,281 New Options were granted on May 26, 2021.
- Participation Rate: Approximately 100% of eligible option holders elected to exchange their options.
Material Changes
The primary material change is the modification of the exercise price for the new options granted to replace the old ones:
- U.S. Tax Subjects: The exercise price is set at $7.00 per ADS (fair market value on April 12, 2021).
- Non-U.S. Tax Subjects: The exercise price is set at $5.00 per ADS, or potentially $4.30 per ADS contingent on future financial performance.
Outlook, Risks, and Contingencies
The filing outlines specific financial performance contingencies that could lower the exercise price for non-U.S. tax subjects to $4.30 per ADS. These conditions are:
- 2021 Target: Net revenues of at least $100 million AND negative EBITDA of less than $40 million.
- 2022 Target: Net revenues of at least $130 million AND negative EBITDA of less than $20 million.
Other terms, including expiration dates and vesting schedules, remain unchanged from the original options.
Investor Verification Checklist
- Verify the final exercise price assigned to non-U.S. tax subjects based on the company's actual 2021 and 2022 financial results.
- Confirm the total number of outstanding options post-exchange (2,805,281 ADSs).
- Review the company's subsequent filings for actual revenue and EBITDA figures to determine if the $4.30 contingent price was triggered.